Ryan Scott
Articles
Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma
January 17, 2023
Article
Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.
Lutathera Prolongs PFS in Patients with Progressive Neuroendocrine Pancreatic Tumors
January 16, 2023
Article
At a median follow-up of 40 months, patients with unresectable, progressive neuroendocrine pancreatic tumors achieved an 80% progression-free survival rate with Lutathera.
Triplet Regimen of COM701, BMS-986207, and Nivolumab Shows Antitumor Activity in Platinum-Resistant Ovarian Cancer
January 15, 2023
Article
Patients with heavily pretreated, platinum-resistant ovarian cancer showed promising responses with a triplet regimen consisting of COM701, BMS-986207, and nivolumab.
Black Women With HR+ Breast Cancer Experience Inferior Outcomes, Despite Comparable Recurrence Scores
January 01, 2023
Article
Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.
Zimberelimab Monotherapy Proves Safe, Effective in PD-L1–Positive Cervical Cancer
December 05, 2022
Article
Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
Neratinib Yields Robust Responses in Patients with HER2-Mutated Cervical Cancer
October 10, 2022
Article
Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.
Oral SERDS Open New Door in ESR1-Mutant, ER-Positive Breast Cancer
August 20, 2022
Article
Aditya Bardia, MD, MPH, discusses ongoing research with oral SERDs, such as elacestrant, and highlights what these agents could represent for patients with estrogen receptor–positive breast cancer.
Tremelimumab Plus Durvalumab Bests Sorafenib OS Rates In Frontline HCC Treatment
July 17, 2022
Article
Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.
Zanubrutinib Associated With Better Quality of Life Vs Bendamustine/Rituximab in CLL/SLL
July 03, 2022
Article
Investigators have identified that zanubrutinib may improve the subpar health-related quality of life for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Addition of HER2-Vaxx Vaccine to Standard Chemotherapy Prolongs Overall Survival in HER2+, Advanced Gastric/GEJ Cancer
July 03, 2022
Article
The addition of the HER2-Vaxx vaccine to chemotherapy resulted in 41.5% reduction in the risk of death compared with chemotherapy alone among patients with gastric cancers.